Skip to main content
. 2014 Dec 10;6(4):2009–2022. doi: 10.18632/oncotarget.2987

Figure 3. Synergistic antitumor efficacy of AZD4547 and cetuximab on SNU16 cells both in vitro and in vivo.

Figure 3

A) Combination therapy with AZD4547 and cetuximab resulted in a significant increase in cell growth toxicity in SNU16 cells. Cells were treated with increasing concentrations of the indicated drugs for 72 hours. The CI/fractional effects curve showed the synergistic anti-proliferative effects of the combination drugs. Multiple drug analyses were conducted by calculating CI values. Data (n = 6) are presented as mean ± SD. * p < 0.01 combination therapy vs. AZD4547 or cetuximab alone. SNU16 cells were treated with 10 nM AZD4547 and 1 uM cetuximab for 24 hours, and the whole cell lysates were collected and analyzed by western blot. Combination therapy with AZD4547 and cetuximab synergistically inhibited phosphorylation of ERK1/2. B) Combination therapy with AZD4547 and cetuximab resulted in synergistic antitumor efficacy in SNU16 xenografts. Groups of SNU16 tumor-bearing mice (n = 6) were treated daily with vehicle (PBS), AZD4547 2 mg/kg q.d., cetuximab 1 mg per animal i.v., and AZD4547 2 mg/kg q.d. plus cetuximab 1 mg per animal i.v.. Cetuximab was administrated on days 1, 4, 7, 11 and 14. The tumor volume, tumor weight and animal body weight were measured and calculated as described in the Materials and Methods. Data (n = 6) are presented as mean ± SD. * p < 0.001 PBS vs. AZD4547, cetuximab and combination therapy.